Opinion|Videos|September 13, 2024
Closing Thoughts From The Panel On Pneumococcal Vaccination
The panel of pneumococcal vaccination experts offer their concluding insights and perspectives on the current landscape of pneumococcal vaccines.
Advertisement
Episodes in this series
Advertisement
Related to this article
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5